Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials.

Timo Vesikari, Jan Hendrik Richardus, Johan Berglund, Tiina Korhonen, Carl-Erik Flodmark, Ann Lindstrand, Sven Arne Silfverdal, Vinod Bambure, Adrian Caplanusi, Ilse Dieussaert, Sumita Roy-Ghanta, David W Vaughn

Research output: Contribution to journalArticlepeer-review

5 Citations (SciVal)

Abstract

During the influenza pandemic 2009-2010, an AS03- adjuvanted A(H1N1)pdm09 vaccine was used extensively in children 6 months of age and older, and during the 2010-2011 influenza season, the A(H1N1)pdm09 strain was included in the seasonal trivalent inactivated influenza vaccine (TIV) without adjuvant. We evaluated the immunogenicity and safety of TIV in children previously vaccinated with the AS03-adjuvanted A(H1N1)pdm09 vaccine.
Original languageEnglish
Pages (from-to)774-782
JournalPediatric Infectious Disease Journal
Volume34
Issue number7
DOIs
Publication statusPublished - 2015

Subject classification (UKÄ)

  • Pediatrics

Fingerprint

Dive into the research topics of 'Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials.'. Together they form a unique fingerprint.

Cite this